A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age-Reference-Cited by-同舟云学术

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Chu Kai¹,Hu Yuemei¹,Pan Hongxing¹,Wu Jingliang²,Zhu Dandan²,Young Mariano M.³,Luo Li⁴^ORCID,Yi Zhuobiao³,Giardina Peter C.⁵,Gruber William C.³,Scott Daniel A.³,Watson Wendy³

Affiliation:

1. Department of Vaccine Clinical Evaluation, Jiangsu Center for Disease Control and Prevention, Nanjing, JS, P. R. China

2. Department of Infectious Disease, Huaiyin Center for Disease Control and Prevention, Huai’an, JS, P. R. China

3. Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA

4. Clinical Development, Pfizer Vaccine Research, Beijing, P. R. China

5. Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA

Funder

Pfizer Inc

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2235926

Reference33 articles.

1. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15

2. Acute Bacterial Sinusitis in Children

3. Etiology of Acute Otitis Media in Children Less Than 5 Years of Age

4. Protracted bacterial bronchitis: reinventing an old disease

5. World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. [accessed 2022 June 28]. https://apps.who.int/iris/bitstream/handle/10665/310970/WER9408-85-103.pdf?sequence=2&isAllowed=y.